Tafluprost is well tolerated in OHT eyes

Article

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT).

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT), reveals an investigation in the British Journal of Ophthalmology.

Dr Elena Milla and her team, Glaucoma and Genetics Unit, Institut Comtal d'Oftalmologia, Barcelona, Spain, conducted a prospective non-interventional, multicentre, observational study on 134 patients. Follow-ups were completed at baseline and one and three months post-treatment.

Five ocular surface symptoms were evaluated as absent, mild, moderate and severe. Tear break-up time, keratitis, conjunctival hyperaemia, blepharitis, Schirmer test and tear meniscus were all assessed in each patient.

A significant improvement in all symptoms was seen in 53% of patients with OHT. This included stinging/burning/irritation, itching, foreign body sensation, tearing and dryness sensation three months after treatment.

All signs except the Schirmer test results improved in the OHT patients. In the glaucomatous eyes the keratitis, hyperaemia and tear meniscus improved at one and three months post-treatment.

Preservative-free tafluprost is a well-tolerated hypotensive agent that can be used to treat naïve eyes and eyes with ocular surface problems.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.